These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

205 related items for PubMed ID: 20048722

  • 21. Primary mutations selected in vitro with raltegravir confer large fold changes in susceptibility to first-generation integrase inhibitors, but minor fold changes to inhibitors with second-generation resistance profiles.
    Goethals O, Vos A, Van Ginderen M, Geluykens P, Smits V, Schols D, Hertogs K, Clayton R.
    Virology; 2010 Jul 05; 402(2):338-46. PubMed ID: 20421122
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Dynamic patterns of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies.
    Canducci F, Sampaolo M, Marinozzi MC, Boeri E, Spagnuolo V, Galli A, Castagna A, Lazzarin A, Clementi M, Gianotti N.
    AIDS; 2009 Feb 20; 23(4):455-60. PubMed ID: 19165083
    [Abstract] [Full Text] [Related]

  • 27. Genotypic coreceptor analysis.
    Sierra S, Kaiser R, Thielen A, Lengauer T.
    Eur J Med Res; 2007 Oct 15; 12(9):453-62. PubMed ID: 17933727
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. HIV-1 integrase inhibitors: 2005-2006 update.
    Dayam R, Gundla R, Al-Mawsawi LQ, Neamati N.
    Med Res Rev; 2008 Jan 15; 28(1):118-54. PubMed ID: 17979144
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Raltegravir susceptibility and fitness progression of HIV type-1 integrase in patients on long-term antiretroviral therapy.
    Buzón MJ, Marfil S, Puertas MC, Garcia E, Clotet B, Ruiz L, Blanco J, Martinez-Picado J, Cabrera C.
    Antivir Ther; 2008 Jan 15; 13(7):881-93. PubMed ID: 19043922
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Broad advances in understanding HIV resistance to antiretrovirals: report on the XVII International HIV Drug Resistance Workshop.
    Mascolini M, Larder BA, Boucher CA, Richman DD, Mellors JW.
    Antivir Ther; 2008 Jan 15; 13(8):1097-113. PubMed ID: 19195337
    [Abstract] [Full Text] [Related]

  • 38. Cenicriviroc, an orally active CCR5 antagonist for the potential treatment of HIV infection.
    Klibanov OM, Williams SH, Iler CA.
    Curr Opin Investig Drugs; 2010 Aug 15; 11(8):940-50. PubMed ID: 20721836
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. GSK-1349572, a novel integrase inhibitor for the treatment of HIV infection.
    Vandekerckhove L.
    Curr Opin Investig Drugs; 2010 Feb 15; 11(2):203-12. PubMed ID: 20112170
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.